Bristol Myers Squibb…has discontinued development of BMS-986497 (ORM-6151), the CD33-targeting degrader-antibody conjugate (DAC) it acquired from South Korea-based Orum Therapeutics (KOSDAQ: 475830) in 2023, after reviewing Phase I clinical data

BMS-986497 - BMS

Sep 18, 2026